KIA
REGN icon

Kraematon Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Kraematon Investment Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30
Closed -$21.6K – 215
2022
Q4 		$21.6K Buy
+30
New +$22.1K 0.02% 164

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Kraematon Investment Advisors's REGN Position: Q1 2023 in Review

Kraematon Investment Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2023, closing a stake of 30 shares — an estimated $21.6K sold.

Kraematon Investment Advisors first reported a position in REGN in Q4 2022 and held it in 1 quarter. The position peaked at $21.6K in Q4 2022. 1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

  • Kraematon Investment Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Kraematon Investment Advisors sold 30 Regeneron Pharmaceuticals shares in Q1 2023, an estimated $21.6K.
  • Kraematon Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Kraematon Investment Advisors's Regeneron Pharmaceuticals position peaked at $21.6K in Q4 2022.
  • 1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Kraematon Investment Advisors's 13F filing for Q1 2023, filed 13 Apr 2023.